InvestorsHub Logo
icon url

DonDonDonDon

04/26/21 11:03 AM

#161717 RE: LifeLongLearner #161716

To say that Leronlimab has failed its trials is like saying Babe Ruth was a failure because you have redefined a home run as a ball hit over 1,000 feet. If you play with the rules enough, anything can be defined as a failure.


Leronlimab did not have stat sig at its primary endpoint. That is the definition of a successful trial. Leronlimab did not come close. You are the one trying to change the rules by disregarding this and looking at cherrypicked data of small subgroups.
icon url

misiu143

04/26/21 11:07 AM

#161720 RE: LifeLongLearner #161716

LifeLongLerner ,
, You are just left wondering , how can this be "

Exactly.

sometimes I am thinking , since our company saying nothing except compliments to FDA at any possibly moment ..

We the shareholders should collect some money and take FDA to court , at least with the few things we know for sure their decision is corrupted ..

I will be in

All imo
icon url

Leronlimab4DaWin

04/26/21 11:52 AM

#161728 RE: LifeLongLearner #161716

You realize that in the 8K the SAEs were actually the same for the LL arm as the SoC right? The whole premise of "no SAEs" is a big fallacy. The only thing the bulls could hang their hat on in the CD10 trial was SAE reduction!!! No look at CD12 SAEs... ugh oh

Why did Nader say the aren't doing CD16/CD17 in the US? Did the FDA shut them down for COVID?